Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
8 080,74 pts
-0.81%


Last updated : 19/11/2026 - 17h36 (last close)
Last close data
🏠 Home   ➤    Stock news

DBV Technologies shares decline nearly 3%, among the largest drops in the SBF 120

The Châtillon biotech company is retreating at midday, within an SBF 120 itself in decline. The stock extends a downward trend established over several weeks, despite the filing of its regulatory dossier with the FDA at the end of September.


DBV Technologies shares decline nearly 3%, among the largest drops in the SBF 120

A stock below its three moving averages, with an RSI at 35

DBV Technologies declines 2.78% to €1.85 in trading, placing it among the largest drops in the SBF 120, an index losing 0.94%. The decline brings the stock's three-month loss to 36.04%, following a -19.73% decline over the last month alone. The price stands 13.10% below the MA20 (€2.13) and 40.10% below the MA200 (€3.09).

The RSI at 35 remains close to the oversold zone without entering it, while the support level at €1.92, now breached, gives way to an absence of immediate technical floor. The filing of the biological license application with the FDA for the peanut allergy patch, announced on September 30, had sparked a rebound on the same day. The stock erased it as early as October 1 by falling back below €2.

Cumulative short positions climb to 4.40% of capital

According to the declarations reviewed, four funds cumulate 4.40% of capital in net short position, compared to 3.51% thirty days ago. The increase of 0.89 percentage points in one month shows that the bearish bet is strengthening without accelerating. These positions indicate that institutional investors remain positioned against the stock, or are seeking to hedge an exposure, a few months ahead of a regulatory deadline that remains the primary source of information on the file.

In its latest results, published on July 16 for the first half of 2026, the company stated it had cash reserves ensuring financing through the third quarter of 2027. It generates still marginal revenue, with the progress of the FDA file constituting the main benchmark for the market.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours